natgillin/translations-raw huggingface dataset:
In the treatment of newly diagnosed multiple myeloma, the recommended dose ranges between 10 and 25 mg per day, depending on the other cancer medicines the patient is taking.
Pri zdravljenju novo odkritega multiplega mieloma znaša priporočeni odmerek med 10 in 25 mg na dan, kar je odvisno od drugih zdravil za zdravljenje raka, ki jih jemlje bolnik.
In the treatment of Paget’s disease of the bone, Aclasta must only be used by a doctor who has experience in the treatment of the disease.
Pri zdravljenju Pagetove bolezni kosti sme zdravilo Aclasta uporabljati samo zdravnik, ki ima izkušnje z zdravljenjem te bolezni.
In the treatment of Paget’s disease of the bone, Zoledronic acid Teva Pharma must only be used by a doctor who has experience in the treatment of the disease.
Pri zdravljenju Pagetove bolezni kosti sme zdravilo Zoledronska kislina kislina Teva Pharma uporabljati samo zdravnik, ki ima izkušnje z zdravljenjem te bolezni.
In the treatment of Paget’s disease, Zoledronic acid Teva Generics must only be used by a doctor who has experience in the treatment of the disease.
Pri zdravljenju Pagetove bolezni sme zdravilo Zoledronska kislina Teva Generics uporabljati samo zdravnik, ki ima izkušnje z zdravljenjem te bolezni.
in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with
parcialnih napadov s sekundarno generalizacijo ali brez nje pri odraslih, mladostnikih in otrocih, od 4. leta starosti, z epilepsijo
in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with
parcialnih napadov s sekundarno generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih od 1 meseca starosti, z epilepsijo
in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with
parcialnih napadov s sekundarno generalizacijo ali brez nje pri odraslih, mladostnikih, otrocih in dojenčkih, od 1 meseca starosti, z epilepsijo
In the treatment of patients with multiple myeloma who have received at least one prior therapy, and in the treatment of mantle cell lymphoma, the recommended dose of Revlimid is 25 mg a day.
Pri zdravljenju bolnikov z multiplim mielomom, ki so prejeli vsaj eno predhodno zdravljenje, je priporočeni odmerek zdravila Revlimid 25 mg na dan.
In the treatment of thrombocytopenia associated with hepatitis C, a higher proportion of patients who took Revolade tested negative for hepatitis C, compared with those who took placebo (23% versus 14% in the first study, and 19% versus 13% in the second study).
Pri zdravljenju trombocitopenije, povezane s hepatitisom C, je bil test za prisotnost virusa hepatitis C negativen pri večjem deležu bolnikov, ki so jemali zdravilo Revolade, kot pri bolnikih, ki so prejemali placebo (23 % v primerjavi s 14 % v prvi študiji in 19 % v primerjavi s 13 % v drugi študiji).
In the treatment of visual impairment due to CNV secondary to PM, many patients may only need one or two injections during the first year, while some patients may need more frequent treatment (see section 5.1).
Pri zdravljenju okvare vida zaradi horoidalne neovaskularizacije, do katere pride zaradi degenerativne kratkovidnosti, lahko številni bolniki potrebujejo samo eno ali dve injekciji v prvem letu, nekateri bolniki pa potrebujejo pogostejše injiciranje zdravila (glejte poglavje 5.1).
In the treatment of visual impairment due to CNV secondary to PM, many patients may only need one or two injections during the first year, while some patients may need more frequent treatment.
Pri zdravljenju okvare vida zaradi horoidalne neovaskularizacije, do katere pride zaradi degenerativne kratkovidnosti, lahko številni bolniki potrebujejo samo eno ali dve injekciji v prvem letu, nekateri bolniki pa potrebujejo pogostejše injiciranje zdravila.
In the treatment phase, because food intake is reduced as when using a traditional non-medical calorie restriction method, care must be taken to ensure that protein, vitamins, essential fatty acids and minerals supplied by the consumed daily food ration meet minimal recommended requirements in order to ensure a complete and balanced nutritional supply.
Ko je vnos hrane zmanjšan pri tradicionalnih metodah omejevanja kalorij brez uporabe zdravil, je treba v času zdravljenja zagotoviti dnevno količino beljakovin, vitaminov, esencialnih maščobnih kislin in mineralov, ki ustreza najmanjšim priporočenim zahtevam za popolno in uravnoteženo prehransko oskrbo.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8 % of 2,557 Optruma treated patients and 11.1 % of 2,576 placebo treated patients.
V populaciji, pri kateri so raloksifen uporabljali za zdravljenje, so zdravljenje zaradi kateregakoli od kliničnih neželenih dogodkov prekinili pri 12,8 % od 2557 bolnic, zdravljenih z zdravilom Optruma, in pri 11,1 % od 2576 bolnic, ki so prejemale placebo.
In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8 % of 2,557 raloxifene treated patients and 11.1 % of 2,576 placebo treated patients.
V populaciji, pri kateri so raloksifen uporabljali za zdravljenje, so zdravljenje zaradi katerega koli od kliničnih neželenih dogodkov prekinili pri 12,8 % od 2.557 bolnic, zdravljenih z raloksifenom, in pri 11,1 % od 2.576 bolnic, ki so prejemale placebo.
In the treatment- naïve MRCC study, 27% patients on sunitinib and 15% of patients on IFN- had an LVEF value below the lower limit of normal.
V študiji še nezdravljenega MRCC je imelo LVEF pod spodnjo mejo normale 27 % bolnikov, ki so prejemali sunitinib, in 15 % bolnikov, ki so prejemali IFN-.
In the trial comparing Levemir vs insulin degludec, the rate of hyperglycaemic episodes with ketosis was significantly higher for Levemir, 1.09 and 0.68 episodes per patient-year of exposure, respectively.
V preskušanju, v katerem so zdravilo Levemir primerjali z insulinom degludek, je bil delež hiperglikemičnih epizod s ketozo pri uporabi zdravila Levemir pomembno večji (1,09 v primerjavi z 0,68 epizod na bolnik-leto izpostavljenosti).
In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).
V preskušanju za preprečevanje kliničnih zlomov po nedavnem zlomu kolka so ravni vitamina D rutinsko merili, vendar je večina bolnikov prejela začetni odmerek vitamina D pred dajanjem zoledronske kisline (glejte poglavje 4.2).
In the trial in type 2 diabetic patients (RIO-Diabetes) who were overweight or obese treated with metformin or sulfonylurea improvements in HbA1c and body weight were observed.
V preskušanju pri pretežkih ali debelih diabetikih tipa 2 (RIO – Diabetes), ki so dobivali metformin ali sulfonilsečnino, so ugotovili izboljšanje HbA1c in telesne mase.
In the TRYPHAENA trial, diarrhoea occurred in 72.3% of patients treated with neoadjuvant Perjeta+TCH and 61.4% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC.
V preskušanju TRYPHAENA se je diareja pojavila pri 72,3 % bolnikov, ki so se neoadjuvantno zdravlili z zdravilom Perjeta in shemo TCH, ter pri 61,4 % bolnikov, ki so se neoadjuvantno zdravili s kombinacijo zdravila Perjeta, trastuzumaba in docetaksela po shemi FEC.
In the TRYPHAENA trial, rash occurred in 36.8% of patients treated with neoadjuvant Perjeta + TCH and 20.0% of patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC.
V preskušanju TRYPHAENA se je izpuščaj pojavil pri 36,8 % bolnikov, ki so se neoadjuvantno zdravili z zdravilom Perjeta in shemo TCH, in pri 20,0 % bolnikov, ki so se neoadjuvantno zdravili s kombinacijo zdravila Perjeta, trastuzumaba in docetaksela po shemi FEC.
In the TRYPHAENA trial, the incidence of NCI-CTCAE v.3 Grade 3-4 neutropenia was 85.3% in patients treated with neoadjuvantPerjeta + TCH and 77.0% in patients treated with neoadjuvant Perjeta, trastuzumab and docetaxel following FEC, including 66.7% and 59.5% Grade 4 neutropenia, respectively.
V preskušanju TRYPHAENA je bila incidenca nevtropenije stopnje 3–4 po merilih NCI-CTCAE (različica 3) 85,3 % pri bolnikih, ki so se neoadjuvantno zdravili z zdravilom Perjeta in shemo TCH, ter 77,0 % pri bolnikih, ki so se neoadjuvantno zdravili s kombinacijo zdravila Perjeta, trastuzumaba in docetaksela po shemi FEC, pri čemer se je nevtropenija stopnje 4 pojavila pri 66,7 % bolnikih, ki so se neoadjuvantno zdravili z zdravilom Perjeta in shemo TCH in 59,5 % bolnikih, ki so se neoadjuvantno zdravili s kombinacijo zdravila Perjeta, trastuzumaba in docetaksela po shemi FEC.
In the TVC and TVC-naïve cohorts, the vaccine’s efficacy was demonstrated against high-grade cervical lesions at end of study (Table 5).
V kohortah TVC in naivni TVC ob koncu študije so učinkovitost cepiva dokazali proti visokostopenjskim spremembam materničnega vratu (preglednica 5).
In the TVC and TVC-naïve cohorts, the vaccine’s efficacy was demonstrated against high-grade cervical lesions at end of study (Table 5).
V kohortah TVC in naivni TVC so ob koncu študije učinkovitost cepiva dokazali proti visokostopenjskim spremembam materničnega vratu (preglednica 5).
In the twelve controlled trials, the rate of infection was 1.49 per patient year in the Trudexa treated patients and 1.42 per patient year in the placebo and active control-treated patients.
V dvanajstih kontroliranih preskušanjih je bil delež okužb 1,49 na bolnik-leto med bolniki, ki so dobivali Trudexo, in 1,42 na bolnik-leto med bolniki, ki so dobivali placebo oziroma kontrolno
In the two 12 weeks studies (Trials 1 and 2), 739 patients received ospemifene and 724 patients received placebo.
V dveh 12-tedenskih študijah (preskušanji 1 in 2) je 739 bolnic prejemalo ospemifen in 724 bolnic je prejemalo placebo.
In the two double-blind, placebo–controlled phase 3 studies in Peyronie’s disease, 65.5% of Xiapex-treated patients developed penile haematoma and 14.5% developed penile ecchymosis.
V dveh dvojno slepih, s placebom nadzorovanih študijah faze 3 za Peyroniejevo bolezen se je pri 65,5 % bolnikov, zdravljenih z zdravilom Xiapex, razvil hematom penisa, pri 14,5 % pa se je razvila ekhimoza penisa.
In the two multi-centre open-label, single-arm phase II clinical trials a total of 202 patients were treated with vinflunine.
V dveh multicentričnih odprtih kliničnih preskušanjih II. faze brez kontrolne skupine so z vinfluninom zdravili 202 bolnika.
In the two ongoing studies (ELT116826 and ELT116643), cytogenetic abnormalities have been detected in 4/28 (14%) and 4/62 (6%) subjects in each study.
V dveh študijah, ki še potekata (študijah ELT116826 in ELT116643), so citogenetske nepravilnosti odkrili pri 4/28 (14 %) oziroma pri 4/62 (6 %) preiskovancev.
In the two other studies, Rasagiline ratiopharm was given as ‘add-on’ to patients with later stage disease who were already being treated with levodopa, and compared with placebo and another medicine entacapone (also used as add-ons).
V dveh drugih študijah so zdravilo Razagilin ratiopharm dajali kot dopolnilno zdravljenje bolnikom z napredovalo boleznijo, ki so se že zdravili z levodopo, ter ga primerjali s placebom in drugim zdravilom entakaponom (ki se prav tako uporablja kot dopolnilno zdravljenje).
In the two Phase 3 placebo-controlled clinical studies where patients received Cayston for 28 days, the most frequently occurring adverse reactions to Cayston were cough (58%), nasal congestion (18%), wheezing (15%), pharyngolaryngeal pain (13.0%), pyrexia (12%) and dyspnoea (10%).
V dveh s placebom kontroliranih kliničnih študijah faze 3, v katerih so bolniki zdravilo Cayston prejemali 28 dni, so bili najpogostejši neželeni učinki povezani z zdravilom Cayston kašelj (58%), zamašen nos (18%), sopenje (15%), faringolaringalna bolečina (13%), pireksija (12%) in dispneja (10%).
In the two Phase III studies in non-Hodgkin’s lymphoma and multiple myeloma patients (AMD3100-3101 and AMD3100-3102, respectively), a total of 301 patients were treated in the Mozobil and G-CSF group and 292 patients were treated in the placebo and G-CSF group.
V dveh študijah faze III pri bolnikih z ne-Hodgkinovim limfomom (AMD3100-3101) in multiplim mielomom (AMD3100-3102) so zdravili 301 bolnikov v skupini z zdravilom Mozobil in G-CSF ter 292 bolnikov v skupini s placebom in G-CSF.
In the two Phase III studies, 4 out of 563 (0.7%) patients in the 10 mg/kg group and 27 out of 559 (4.8%) patients in the 1 mg/kg group tested positive for persistent presence of anti-belimumab antibodies.
V dveh študijah III. faze so imeli pozitiven izvid stalne prisotnosti protiteles proti belimumabu 4 od 563 (0,7 %) bolnikov v skupini, ki je prejemala 10 mg/kg, in 27 od 559 (4,8 %) bolnikov v skupini, ki je prejemala 1 mg/kg.
In the two pivotal phase 3 studies in which patients were dosed with 290 micrograms of linaclotide once daily, linaclotide was only detected in 2 out of 162 patients approximately 2 h following the initial linaclotide dose (concentrations were 0.241 ng/ml to
V dveh ključnih študijah 3. faze, pri katerih so bolniki prejemali odmerek 290 mikrogramov linaklotida enkrat na dan, so linaklotid zaznali pri samo 2 od 162 bolnikov približno 2 uri po začetnem odmerku linaklotida (koncentracije so bile v razponu od
In the two placebo-controlled phase III trials, infections were more often observed in patients treated with Stivarga as compared to patients receiving placebo (all grades: 31.0% vs.
V dveh s placebom nadzorovanih preskušanjih III. faze so okužbe pogosteje opazili pri bolnikih, zdravljenih z zdravilom Stivarga, kot pri bolnikih, ki so prejemali placebo (vse stopnje: 31,0 % v primerjavi s 14,4 %).
In the two placebo-controlled phase III trials, tests on thyroid stimulating hormone (TSH) showed post baseline >ULN in 26.1% of patients treated with Stivarga and in 15.1% of patients receiving placebo.
V dveh s placebom nadzorovanih preskušanjih III. faze so preiskave glede vrednosti tiroideo stimulirajočega hormona (TSH) pokazale > ULN glede na izhodiščne vrednosti pri 26,1 % bolnikov, zdravljenih z zdravilom Stivarga, in 15,1 % bolnikov, ki so prejemali placebo.
In the two placebo-controlled phase III trials, the overall incidence of hemorrhage was 19.3% in patients treated with Stivarga.
V dveh s placebom nadzorovanih preskušanjih III. faze je bila celokupna incidenca hemoragij 19,3 % pri bolnikih, zdravljenih z zdravilom Stivarga.
In the two placebo-controlled studies, 9 patients reported a bleeding event that was considered serious (5 [6.0%] romiplostim, 4 [9.8%] placebo; Odds Ratio [romiplostim/placebo] = 0.59; 95% CI = (0.15, 2.31)).
V dveh s placebom kontroliranih študijah je pri 9 bolnikih prišlo do krvavitve, ki je bila ocenjena za resno (5 [6,0%] romiplostim, 4 [9,8%] placebo, razmerje obetov [romiplostim/placebo] = 0,59, 95% IZ = (0,15, 2,31)).
In the two placebo-controlled studies, 9 patients reported a bleeding event that was considered serious (5 [6.0%] romiplostim, 4 [9.8%] placebo; Odds Ratio [romiplostim/placebo] = 0.59; 95% CI = (0.15, 2.31)).
V dveh s placebom kontroliranih študijah je pri 9 bolnikih prišlo do krvavitve, ki je bila ocenjena za resno (5 [6,0%] romiplostim, 4 [9,8%] placebo, razmerje obetov [romiplostim/placebo] = 0,59; 95% IZ = (0,15, 2,31)).
In the two primary efficacy studies of general populations, the mean per-subject proportion of successful intercourse attempts were 57 and 67% on tadalafil 5 mg, 50% on tadalafil 2.5 mg as compared to 31 and 37% with placebo.
V dveh primarnih študijah učinkovitosti splošne populacije je bilo v povprečju pri bolnikih, zdravljenih s tadalafilom 5 mg, uspešnih 57 in 67% poskusov spolnega odnosa, sorazmerno z bolniki, zdravljenimi s tadalafilom 2,5 mg 50%, v primerjavi s 31 in 37% pri placebu.
In the two primary efficacy studies of general populations, the mean per-subject proportion of successful intercourse attempts were 57 and 67% on tadalafil 5 mg, 50% on tadalafil 2.5 mg as compared to 31 and 37% with placebo.
V dveh primarnih študijah učinkovitosti splošne populacije je bilo v povprečju pri bolnikih, zdravljenih z zdravilom Tadalafil Mylan 5 mg, uspešnih 57 in 67% poskusov spolnega odnosa, sorazmerno z bolniki, zdravljenimi z zdravilom Tadalafil Mylan 2.5 mg 50%, v primerjavi s 31 in 37% pri placebu.
In the two studies of brain and spine abnormalities taken together, scans taken with Optimark had a score increase of 0.63 points on average from a ‘baseline’ of 1.58 points without Optimark.
V dveh študijah nepravilnosti v možganih in hrbtenici je bilo na slikah, posnetih ob jemanju zdravila Optimark, doseženo povprečno izboljšanje rezultata za 0,63 točke (izhodiščna vrednost brez zdravila Optimark je bila 1,58 točke).
In the two studies with Ipreziv taken alone compared with placebo, patients had an average fall in systolic blood pressure of about 13.5 mmHg on Ipreziv 40 mg and a fall of about 14.5 mmHg on Ipreziv 80 mg after 6 weeks.
40-miligramski odmerek zdravila Ipreziv, po šestih tednih sistolični krvni tlak v povprečju znižal za okoli 13,5 mmHg, pri bolnikih, ki so jemali 80-miligramski odmerek zdravila Ipreziv, pa za okoli 14,5 mmHg.
In the two studies, the average amount of phosphate in the blood during treatments with Sevelamer carbonate Zentiva or Renagel was similar.
V obeh študijah je bila povprečna raven fosfata v krvi med zdravljenjem z zdravilom Sevelamer carbonate Zentiva in zdravilom Renagel podobna.
In the two surgeries that occurred during the study, Nuwiq was rated as excellent in preventing bleeding episodes.
Pri dveh kirurških posegih, ki so ju opravili med študijo, je bilo zdravilo Nuwiq ocenjeno kot odlično pri preprečevanju krvavitev.
In the two-year placebo-controlled study, hypertension was reported as an adverse event in 6.5% of patients on fingolimod 0.5 mg and in 3.3% of patients on placebo.
V dvoletni, s placebom kontrolirani študiji so med neželenimi učinki poročali o hipertenziji pri 6,5 % bolnikov, ki so prejemali fingolimod 0,5 mg, in pri 3,3 % bolnikov, ki so prejemali placebo.
In the twoplacebo-controlled studies adverse events were generally mild to moderate in severity.
V teh dveh s placebom nadzorovanih študijah so bili neželeni učinki na splošno blagi do zmerni.
In the unadjuvanted control group, as well as in the adjuvant control group, all animals died or had to be euthanized as they were moribund, three to four days after the start of challenge.
V kontrolnih skupinah so vse živali – tako tiste, ki niso dobile adjuvansa, kot tiste, ki so ga – poginile ali so jih morali evtanazirati, ker so bile tik pred poginom, od tri do štiri dni po začetku provokacije.
In the unadjuvanted control group, as well as in the adjuvant control group, all animals died or had to be euthanized as they were moribund, three to four days after the start of challenge.
V kontrolnih skupinah so vse živali – tako tiste, ki niso dobile adjuvansa, kot tiste, ki so ga – poginile ali so jih morali žrtvovati, ker so bile tik pred poginom, od tri do štiri dni po začetku provokacije.
In the unlikely event of a radiation overdose being administered with LeukoScan [99mTc], the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion of the radiolabel.
V primeru prevelike doze sevanja, prejete ob vnosu zdravila LeukoScan [99mTc], kar pa ni verjetno, se absorbirana doza lahko zmanjša s povečanim peroralnim ali intravenskim vnosom tekočin, kar pospeši izločanje radioaktivnega označevalca.
In the unlikely event of the administration of a radiation overdose with LeukoScan, the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion of the radiolabel.
V primeru prevelike doze sevanja, prejete ob vnosu zdravila LeukoScan, kar pa ni verjetno, se absorbirana doza lahko zmanjša s povečanim peroralnim ali intravenskim vnosom tekočin, kar pospeši izločanje radioaktivnega označevalca.
In the US study, a total of 49 subjects with primary immunodeficiency syndromes aged between 5 and 72 years old were treated with Hizentra for up to 15 months.
V študiji v ZDA je bilo skupaj 49 preiskovancev s sindromi primarne imunske pomanjkljivosti starosti med 5 in 72 let, zdravljenih z zdravilom Hizentra v obdobju do 15 mesecev.
In the vandetanib arm, a total of 73 (32%) patients progressed: 64 (28%) by response evaluation criteria in solid tumours (RECIST) progression and 9 (4%) by death in the absence of progression.
V kraku z vandetanibom se je napredovanje pojavilo pri skupaj 73 (32 %) bolnikov; pri 64 (28 %) so ugotovili napredovanje po RECIST (response evaluation criteria in solid tumours – merila za ocenjevanje odziva parenhimskih tumorjev) in 9 (4 %) bolnikov je umrlo, ne da bi se pojavilo napredovanje.
In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatment).
V skupini, ki je prejemala vareniklin, je v primerjavi s skupino, ki je prejemala placebo, več preiskovancev poročalo o razmišljanju o samomoru ali samomorilnem vedenju pred vključitvijo v študijo (osebna anamneza) ter po koncu obdobja, v katerem so prejemali zdravilo (na 33. do 85. dan po zadnjem prejetem odmerku zdravila).
In the varenicline group compared to placebo, a higher proportion of subjects reported suicidal ideation or behaviour prior to enrolment (lifetime history) and after the end of active treatment period (on Days 33 to 85 after the last dose of treatments ).
V skupini, ki je prejemala vareniklin, je v primerjavi s skupino, ki je prejemala placebo, več preiskovancev poročalo o razmišljanju o samomoru ali samomorilnem vedenju pred vključitvijo v študijo (osebna anamneza) ter po koncu obdobja, v katerem so prejemali zdravilo (na 33. do 85. dan po zadnjem prejetem odmerku zdravila).
in the veins (thrombosis)
Nastalih v venah (tromboza)
In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline and the Eylea group wassuperior to laser control.
V študiji VIBRANT je bil primarni cilj učinkovitosti delež bolnikov, ki so pridobili vsaj 15 črk BCVA v 24. tednu v primerjavi z izhodiščnimi vrednostmi in zdravljenje z zdravilom Eylea je bilo superiorno v primerjavi s kontrolno skupino z laserskim zdravljenjem.
In the ViraferonPeg combination trial, 1,530 naïve patients were treated for one year with one of the following combination regimens:
V kliničnem preskušanju kombiniranega zdravljenja z zdravilom ViraferonPeg je 1.530 predhodno nezdravljenih bolnikov eno leto prejemalo enega od naslednjih kombiniranih režimov zdravljenja:
In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions.
V študijah VTEp so se neželeni učinki pojavili pri 11 % bolnikov, ki so se zdravili z apiksabanom v odmerku 2,5 mg dvakrat na dan.
In the Week 96 pooled analysis for patients receiving emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) + rilpivirine hydrochloride in the Phase 3 clinical studies TMC278-C209 and TMC278-C215, HIV-1 isolates from 43 patients had an amino acid substitution associated with NNRTI (n = 39) or NRTI (n = 41) resistance.
V združeni analizi v 96. tednu pri bolnikih, ki so prejemali emtricitabin/dizoproksiltenofovirat fumarat (FTC/TDF) + rilpivirinijev klorid v kliničnih študijah faze III TMC278-C209 in TMC278-C215, je prišlo pri izolatih HIV-1 pri 43 bolnikih do substitucije aminokisline, povezane z rezistenco na NNRTI (n = 39) ali NRTI (n = 41).